World Head Injury Awareness Day

March 20th is World Head Injury Awareness Day! This day is dedicated to raise public attention about the incidence and the wide spectrum of complications after head injuries, ranging from mild concussions to severe brain trauma.

This day serves as a poignant reminder of the importance of prevention and vigilance in mitigating accidents that can lead to such injuries, although sadly, they are not always avoidable.

EVER Pharma is particularly active in those regions of the world where traumatic brain injury is a serious medical and socio-economic burden. Our company is continuously aiming to support countries in their efforts to improve treatment standards in this field of medicine, particularly by emphasizing the long-term consequences of brain trauma.

The AMN (Academy of Multidisciplinary Neurotraumatology) has been identified by EVER Pharma as the optimal medical society for scientific collaboration. Jointly we aim to propagate the important concept of multidisciplinary treatment strategies.

An important milestone for EVER Pharma has been the positive CAPTAIN trial series which consequently led to the first inclusions into brain trauma related treatment guidelines.

One of them is the recently updated Canadian ERABI (Evidence-Based Review of Acquired Brain Injury) guideline, where Cerebrolysin^® is included with a 1b recommendation in the domain attention deficits.

Matching EVER Pharma’s focus on brain trauma, we regularly organize communication platforms to discuss traumatic brain injury and related consequences. One of them will be a webinar held on 17th of April 2024 titled: ‘Cerebrolysin’s evidence from TBI research – Treat early, reduce acute and post-acute complications’. Please register for this very important and interesting webinar.